Dissociation of binding and antiresorptive properties of hydroxybisphosphonates by substitution of the hydroxyl with an amino group.
The purpose of this study was to examine the role of the R1 moiety of bisphosphonates in binding to bone mineral and for antiresorptive action. For this, the R1 chain of three clinically useful hydroxybisphosphonates (etidronate, pamidronate, and olpadronate) was substituted with an amino group. The effects of the aminosubstituted bisphosphonates were compared with those of their hydroxy counterparts in a crystal growth assay and in fetal mouse long bone cultures which are representative of bisphosphonate actions in vivo. It was found that all three aminosubstituted compounds and their hydroxy analogs bound with similar affinity to bone mineral and inhibited the growth of calcium oxalate crystals to the same extent. Surprisingly, the antiresorptive effect of olpadronate was totally abolished by the amino substitution of the hydroxyl group while that of pamidronate was reduced by about six-fold and that of etidronate did not change. These studies demonstrate the involvement of the entire bisphosphonate molecule in the cellular mechanism of antiresorptive action. In addition, the aminosubstituted analog of olpadronate, which lacks any antiresorptive action but retains all other properties of olpadronate, provides an excellent tool for the study of specific cellular effects involved in bisphosphonate action.
Department of Endocrinology and Metabolic Diseases, University Hospital, Leiden, The Netherlands.
E
E
Van Beek
C
C
Löwik
I
I
Que
S
S
Papapoulos
D000588:Amines / Q000737:chemistry; D000704:Analysis of Variance; D000818:Animals; D001665:Binding Sites; D001857:Bone Matrix / Q000187:drug effects / Q000378:metabolism; D001862:Bone Resorption / Q000188:drug therapy*; D002129:Calcium Oxalate / Q000032:analysis / Q000378:metabolism; D003460:Crystallization; D004164:Diphosphonates / Q000494:pharmacology / Q000627:therapeutic use*; D012968:Etidronic Acid / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D051379:Mice; D000077268:Pamidronate; D011247:Pregnancy; D013329:Structure-Activity Relationship
D000588:Amines; D004164:Diphosphonates; D002129:Calcium Oxalate; C055774:olpadronic acid; D012968:Etidronic Acid; D000077268:Pamidronate